{"product_id":"stxs-bcg-matrix","title":"(STXS) Stereotaxis, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Stereotaxis, Inc. BCG Matrix is a ready-made tool for evaluating the company’s products or business units across Stars, Cash Cows, Question Marks, and Dogs. It helps with strategy, portfolio review, and investment analysis, and this page already shows a real preview of the actual report content. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenesis RMN system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenesis RMN is Stereotaxis, Inc.'s flagship robotic magnetic navigation platform and the core hardware behind future scale. It targets complex electrophysiology cases, a niche that keeps expanding as robotic ablation adoption rises in 2025-2026. Its installed base also supports replacement demand over time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOdyssey information system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOdyssey information system is a sticky software layer for interventional labs: it records, shares, and streams procedural data in real time, so its value rises with every robotic room Stereotaxis, Inc. installs. Once embedded, upgrades can expand its workflow and data tools without a full reset. That makes it a strong Star in the BCG view because adoption can scale with the robotic base and support wider lab digitization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuikCAS catheter advancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuikCAS catheter advancement is an automated remote tool for EP catheters, so its use rises with each robotic case. Because it is tied to procedure volume, it can scale faster than capital equipment and support recurring consumable demand. In Stereotaxis, Inc.'s BCG Matrix, that volume-linked pull makes QuikCAS a Star candidate if robotic adoption keeps growing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVdrive navigation platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVdrive navigation platform is a Star for Stereotaxis, Inc. because it supports high-value interventional cases and gains from the company’s installed robotic lab base and repeat use. In fiscal 2025, Stereotaxis kept pushing workflow speed and procedural consistency, which matters most in a niche where small time savings can lift lab throughput.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat use drives recurring demand\u003c\/li\u003e\n\u003cli\u003eInstalled base supports adoption\u003c\/li\u003e\n\u003cli\u003eWorkflow efficiency is a key selling point\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIts role is strongest in labs already using robotic navigation, where stability tools can be pulled into more cases over time. That makes Vdrive a fit for a high-growth niche with durable use per procedure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRMN workflow platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRMN workflow platform combines catheter guidance, software, and room integration, so Stereotaxis can raise value per procedure. If adoption keeps rising, it can move from a niche tool to a durable leader as hospitals standardize robotic magnetic navigation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands revenue beyond hardware.\u003c\/li\u003e\n\u003cli\u003eTies into recurring software use.\u003c\/li\u003e\n\u003cli\u003eBoosts procedure-level economics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobotic EP Stars: Repeat-Use Tools Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenesis RMN, Odyssey, QuikCAS, and Vdrive fit Stars because they sit in growing robotic EP workflows and can scale with each new lab install. Their best trait is repeat use: more procedures means more software, catheter, and room-level demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eGrowth driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenesis RMN\u003c\/td\u003e\n\u003ctd\u003eCore robotic platform\u003c\/td\u003e\n\u003ctd\u003eRobotic case growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOdyssey\u003c\/td\u003e\n\u003ctd\u003eSticky lab software\u003c\/td\u003e\n\u003ctd\u003eInstalled base expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuikCAS\u003c\/td\u003e\n\u003ctd\u003eProcedure-linked tool\u003c\/td\u003e\n\u003ctd\u003eCase volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVdrive\u003c\/td\u003e\n\u003ctd\u003eWorkflow support\u003c\/td\u003e\n\u003ctd\u003eRepeat use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eStereotaxis, Inc. BCG Matrix maps its products by growth and share to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Stereotaxis, Inc. to quickly spot growth, cash cows, and underperformers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Stereotaxis, Inc. that helps validate claims fast and supports better decisions with traceable evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNiobe installed base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNiobe’s installed base is Stereotaxis, Inc.’s clearest cash cow: legacy robotic magnetic navigation systems already in hospitals keep producing service, support, and upgrade revenue with little new selling cost. That mature base turns past placements into recurring cash, so margins are stronger than on new system sales. It is the most stable revenue engine in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOdyssey maintenance revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOdyssey maintenance revenue fits the Cash Cows box because installed labs need software support, networking, and feature updates after the sale. That creates recurring, higher-margin revenue with a much lower customer-acquisition cost than new robotic hardware. For Stereotaxis, Inc., this is a classic mature-platform cash flow stream that helps fund growth even when system sales are uneven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eV-Loop consumable\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eV-Loop consumable is a single-use accessory used in robotic procedures, so every case can trigger another sale. That repeat demand fits a cash cow profile: low growth, but steady recurring revenue and high visibility. In Stereotaxis, Inc.'s latest filings, consumables and disposable tools remain the most repeatable part of the mix, supporting margin stability versus capital equipment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eV-Sono consumable\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eV-Sono consumable is a disposable accessory tied to each interventional case, so Stereotaxis, Inc. can sell it into existing accounts without major capital spend. That makes it a recurring, low-capex cash cow with steady pull-through from the installed base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCase-linked recurring revenue\u003c\/li\u003e\n\u003cli\u003eUses existing customer accounts\u003c\/li\u003e\n\u003cli\u003eLow capital intensity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eV-CAS consumable\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eV-CAS is the disposable layer in Stereotaxis’ installed robotic labs, so its sales track procedure volume, not new system placements. That makes it a classic cash cow: recurring use, low switching, and steady gross-margin cash generation.\u003c\/p\u003e\n\u003cp\u003eManagement does not break out V-CAS revenue separately in public filing detail, but the model benefits when labs run more cases on the existing base, even if capital equipment demand stays uneven.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring disposable revenue\u003c\/li\u003e\n\u003cli\u003eDriven by procedure counts\u003c\/li\u003e\n\u003cli\u003eSupports margin-rich cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstalled Base and Consumables Keep Stereotaxis Cash Flow Steady\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows in Stereotaxis, Inc. are the installed Niobe and Odyssey base plus V-Loop, V-Sono, and V-CAS consumables, because they sell into existing labs with low new-capex and recurring pull-through. In FY2025, this mix stayed the steadier, higher-margin cash source versus uneven robotic system orders. It funds operations when capital demand slows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNiobe\/Odyssey\u003c\/td\u003e\n\u003ctd\u003eInstalled-base service\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eV-Loop\/V-Sono\/V-CAS\u003c\/td\u003e\n\u003ctd\u003eCase-linked repeat sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eStereotaxis, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Stereotaxis, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No mockups, no sample pages—just the complete, professionally formatted file ready for immediate use. Once purchased, the full report is available for download exactly as shown. What you preview is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImaging Model S X-ray system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImaging Model S is a single-plane X-ray system, so it sits in a crowded 2D imaging niche with one X-ray chain rather than higher-end multi-plane setups. Stereotaxis is much stronger in robotic navigation than in commodity imaging, so this product has low relative share and little strategic pull. In BCG terms, it looks more like a Dog than a growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCARTO RMT catheter line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCARTO RMT is a legacy steerable diagnostic and ablation catheter family, and its older SKUs face heavy competition and pricing pressure. In Stereotaxis’ latest filings, the company still shows low overall scale, with 2024 revenue near $29 million and continued net losses, which limits support for aging catheter lines. With weak growth and little product differentiation, this line fits Dog territory in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCELSIUS RMT catheter line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCELSIUS RMT catheter line sits in the Dogs quadrant for Stereotaxis, Inc.: it is a legacy ablation catheter family in a mature, crowded market with slow replacement cycles. It is not a core growth engine, and its role is mainly to support installed-system use. Stereotaxis' growth mix is more tied to newer robotic and disposable offerings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNAVISTAR RMT catheter line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNAVISTAR RMT catheter line is an older robotic catheter family in Stereotaxis, Inc. It fits the Dogs box because volumes are modest, growth is limited, and it is not a major profit driver.\u003c\/p\u003e\n\u003cp\u003eIt still supports the installed robotic base, but the line has little expansion value versus newer products. In FY2025, the key point is low strategic pull, not scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eOlder catheter line\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eModest volume, limited growth\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eUseful, but low profit impact\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy standalone hardware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy standalone hardware fits the Dogs box because older robotic-room peripherals commoditize fast, so replacement demand stays weak and margins stay thin. Stereotaxis, Inc. still spends support time on these units, but they add little scale versus newer magnetic navigation systems. In 2025, that kind of low-growth hardware likely behaves like a maintenance-only line, not a growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSlow replacement cycles\u003c\/li\u003e\n\u003cli\u003eFast commoditization\u003c\/li\u003e\n\u003cli\u003eHigh support load\u003c\/li\u003e\n\u003cli\u003eLow growth leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStereotaxis’ Dog Lines Stay Small, Low-Share, and Under Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStereotaxis, Inc. Dogs are legacy or commodity lines with weak growth and low share. FY2025 scale stayed small, with revenue near $29 million in the latest filing set and net losses still pressuring support for these products. They add maintenance value, but not real growth or margin lift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog line\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImaging Model S\u003c\/td\u003e\n\u003ctd\u003eCommodity 2D imaging\u003c\/td\u003e\n\u003ctd\u003eLow share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy catheters\u003c\/td\u003e\n\u003ctd\u003eSlow growth, pricing pressure\u003c\/td\u003e\n\u003ctd\u003eFY2025 weak scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStandalone hardware\u003c\/td\u003e\n\u003ctd\u003eFast commoditization\u003c\/td\u003e\n\u003ctd\u003eRevenue near $29 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOsypka magnetic ablation catheter\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Osypka magnetic ablation catheter is a Question Mark for Stereotaxis, Inc. because it is still a development-stage asset at end-2025, not a revenue driver. Stereotaxis and Osypka AG are jointly building a catheter that uses Stereotaxis magnetic navigation technology, and success could lift it into a Star if it reaches commercial use. For now, it sits in the pipeline, with value tied to clinical progress and regulatory execution rather than current sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-generation robotic ablation catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNext-generation robotic ablation catheters are a Question Mark for Stereotaxis, Inc. because catheters are high-value consumables, so wins can lift recurring revenue, but share is still unproven. The global electrophysiology ablation market keeps growing as atrial fibrillation cases rise, yet Stereotaxis still needs heavy R\u0026amp;D, clinical proof, and sales spend before launches can scale. That means upside is real, but cash burn comes first.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Genesis hospital placements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew Genesis hospital placements are a question mark for Stereotaxis, Inc. because growth exists, but each deal can take a long sales cycle and depends on hospital capital budgets. Adoption is encouraging, yet the installed base is still small, so conversion has not scaled enough to make placements a cash cow.\u003c\/p\u003e\n\u003cp\u003eUntil placements rise faster and repeat buying improves, this segment stays a question mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational distributor expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStereotaxis’ international distributor model can scale fast, but it is still a Question Mark in BCG terms because non-U.S. demand is uneven and depends on local partner execution. The company has said it sells outside the U.S. through distributors and agents, so market share can lift quickly where clinical access and service support are strong. That upside comes with high risk: weak channel coverage can slow adoption and distort revenue timing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upside, uneven regional penetration\u003c\/li\u003e\n\u003cli\u003eFast share gains, but execution risk stays high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIntegrated robotic lab bundles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntegrated robotic lab bundles can lift Stereotaxis, Inc. deal size by tying robotics, imaging, and software into one hospital purchase. They fit the question mark box because they need capital approval, clinical proof, and long sales cycles before they scale. In 2025\/2026, they look like growth bets, not mature cash engines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand account value.\u003c\/li\u003e\n\u003cli\u003eDepend on hospital capex.\u003c\/li\u003e\n\u003cli\u003eNeed clinical validation.\u003c\/li\u003e\n\u003cli\u003eNot yet a cash producer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStereotaxis’ 2025\/2026 growth bets still need proof to pay off\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStereotaxis, Inc. Question Marks are still mostly pre-revenue bets in 2025\/2026. The Osypka catheter, next-gen ablation catheters, Genesis placements, distributor growth, and integrated lab bundles can all lift recurring sales, but each still needs clinical proof, hospital capex, and tighter execution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eQuestion Mark\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOsypka catheter\u003c\/td\u003e\n\u003ctd\u003eDevelopment stage\u003c\/td\u003e\n\u003ctd\u003eRegulatory delay\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenesis placements\u003c\/td\u003e\n\u003ctd\u003eSmall installed base\u003c\/td\u003e\n\u003ctd\u003eLong sales cycle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235129106697,"sku":"stxs-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/stxs-bcg-matrix.webp?v=1785732832","url":"https:\/\/dcfanalyst.com\/products\/stxs-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}